Uncategorized
John Santilli quoted in Modern Medicine: FDA warns of rare brain infection with MS drug Tecfidera
New oral therapies
Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries.
“Although this is Tecfidera’s first incident tied to PML use in more than 100,000 patients treated, it is a cause for concern for Biogen Idec, as the market for MS treatment continues to become more competitive,” Santilli said.
